The loss of FSCN1 expression sensitized breast cancer cells (MDA-MB-231) to doxorubicin therapy, whereas the expression of FSCN1 in the FSCN1-negative T47-D or SK-BR-3 breast cancer cell line conferred chemoresistance. This evidence concerns the gene FSCN1 and breast carcinoma.